Theravance Biopharma, Inc.

Informe acción NasdaqGM:TBPH

Capitalización de mercado: US$455.0m

Salud financiera de hoja de balance de Theravance Biopharma

Salud financiera controles de criterios 4/6

Theravance Biopharma tiene un patrimonio de los accionistas total de $213.0M y una deuda total de $0.0, lo que sitúa su ratio deuda-patrimonio en 0%. Sus activos y pasivos totales son $382.0M y $169.0M respectivamente.

Información clave

0%

Ratio deuda-patrimonio

US$0

Deuda

Ratio de cobertura de interesesn/a
EfectivoUS$102.43m
PatrimonioUS$213.00m
Total pasivoUS$169.00m
Activos totalesUS$382.00m

Actualizaciones recientes sobre salud financiera

No hay actualizaciones

Recent updates

Shareholders May Be More Conservative With Theravance Biopharma, Inc.'s (NASDAQ:TBPH) CEO Compensation For Now

May 02
Shareholders May Be More Conservative With Theravance Biopharma, Inc.'s (NASDAQ:TBPH) CEO Compensation For Now

Some Confidence Is Lacking In Theravance Biopharma, Inc.'s (NASDAQ:TBPH) P/S

Feb 05
Some Confidence Is Lacking In Theravance Biopharma, Inc.'s (NASDAQ:TBPH) P/S

Upgrade: Analysts Just Made A Sizeable Increase To Their Theravance Biopharma, Inc. (NASDAQ:TBPH) Forecasts

Nov 11
Upgrade: Analysts Just Made A Sizeable Increase To Their Theravance Biopharma, Inc. (NASDAQ:TBPH) Forecasts

Theravance to purchase $95M of ordinary shares

Sep 28

Things Look Grim For Theravance Biopharma, Inc. (NASDAQ:TBPH) After Today's Downgrade

Sep 21
Things Look Grim For Theravance Biopharma, Inc. (NASDAQ:TBPH) After Today's Downgrade

Theravance Biopharma announces $250M capital return program

Sep 19

Theravance Biopharma GAAP EPS of -$0.11, revenue of $11.1M

Aug 04

Theravance: All-Round Failure

Mar 10

Theravance Biopharma, Inc. (NASDAQ:TBPH) Analysts Just Trimmed Their Revenue Forecasts By 27%

Aug 09
Theravance Biopharma, Inc. (NASDAQ:TBPH) Analysts Just Trimmed Their Revenue Forecasts By 27%

Theravance Bio stock falls 6% after nezulcitinib flunks mid-stage COVID-19 induced lung injury study

Jun 21

Theravance Biopharma, Inc. (NASDAQ:TBPH) Analysts Are Reducing Their Forecasts For This Year

May 09
Theravance Biopharma, Inc. (NASDAQ:TBPH) Analysts Are Reducing Their Forecasts For This Year

Theravance Biopharma EPS misses by $0.16, misses on revenue

May 04

Shareholders May Not Be So Generous With Theravance Biopharma, Inc.'s (NASDAQ:TBPH) CEO Compensation And Here's Why

Apr 21
Shareholders May Not Be So Generous With Theravance Biopharma, Inc.'s (NASDAQ:TBPH) CEO Compensation And Here's Why

Don't Ignore The Fact That This Insider Just Sold Some Shares In Theravance Biopharma, Inc. (NASDAQ:TBPH)

Mar 13
Don't Ignore The Fact That This Insider Just Sold Some Shares In Theravance Biopharma, Inc. (NASDAQ:TBPH)

Is Theravance Biopharma, Inc. (NASDAQ:TBPH) Expensive For A Reason? A Look At Its Intrinsic Value

Mar 08
Is Theravance Biopharma, Inc. (NASDAQ:TBPH) Expensive For A Reason? A Look At Its Intrinsic Value

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo ($133.5M) de TBPH superan a sus pasivos a corto plazo ($24.8M).

Pasivo a largo plazo: Los activos a corto plazo ($133.5M) de TBPH no cubren sus pasivos a largo plazo ($144.2M).


Historial y análisis de deuda-patrimonio

Nivel de deuda: TBPH está libre de deudas.

Reducción de la deuda: TBPH actualmente no tiene deuda, sin embargo, no podemos comparar con hace 5 años ya que no disponemos de datos de ese periodo.


Hoja de balance


Análisis de cash runway

En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.

Cash runway estable: TBPH tiene suficiente cash runway para más de 3 años basándose en su flujo de caja libre actual.

Pronóstico de cash runway: Datos insuficientes para determinar si TBPH tiene suficiente cash runway en caso de que su flujo de caja libre siga creciendo o disminuyendo basado en tasas históricas.


Descubre empresas con salud financiera